KRAS-mediated up-regulation of RRM2 expression is essential for the proliferation of colorectal cancer cell lines

Anticancer Research

Volumn 31, Issue 7, 2011, Pages 2535-2539

  Yoshida, Yasuhiro ^a   Tsunoda, Toshiyuki ^a   Doi, Keiko ^a   Tanaka, Yoko ^a   Fujimoto, Takahiro ^a   Machida, Takashi ^a   Ota, Takeharu ^a   Koyanagi, Midori ^a   Takashima, Yasuo ^a   Sasazuki, Takehiko ^b   Kuroki, Masahide ^a   Iwasaki, Akinori ^a   Shirasawa, Senji ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Colon cancer; KRAS; RRM2

Indexed keywords

DNA; K RAS PROTEIN; OXIDOREDUCTASE INHIBITOR; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL PROLIFERATION; CELL STRAIN HCT116; COLONY FORMATION; COLORECTAL CANCER; CONTROLLED STUDY; DNA SYNTHESIS; HUMAN; HUMAN CELL; ONCOGENE K RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM; UPREGULATION;

ADENOCARCINOMA; CELL ADHESION; CELL CULTURE TECHNIQUES; CELL DIVISION; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CULTURE MEDIA, SERUM-FREE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; NEOPLASM PROTEINS; ONCOGENE PROTEINS; POINT MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RNA, SMALL INTERFERING; TUMOR STEM CELL ASSAY; UP-REGULATION;

EID: 79961195301     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Shirasawa S, Furuse M, Yokoyama N and Sasazuki T: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260: 85-88, 1993. (Pubitemid 23122749)
2. Tsunoda T, Takashima Y, Fujimoto T, Koyanagi M, Yoshida Y, Doi K, Tanaka Y, Kuroki M, Sasazuki T and Shirasawa S: Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model. Neoplasia 12: 397-404, 2010.
3. Trobridge P, Knoblaugh S, Washington MK, Munoz NM, Tsuchiya KD, Rojas A, Song X, Ulrich CM, Sasazuki T, Shirasawa S and Grady WM: TGF-beta receptor inactivation and mutant Kras induce intestinal neoplasms in mice via a beta-catenin-independent pathway. Gastroenterology 136: 1680-1688 e1687, 2009.
4. Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N and Rak JW: Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood 105: 1734-1741, 2005. (Pubitemid 40223697)
5. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB and Rosen N: 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18: 39-51, 2010.
6. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S and Bardelli A: Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120: 2858-2866, 2010.
7. Baba I, Shirasawa S, Iwamoto R, Okumura K, Tsunoda T, Nishioka M, Fukuyama K, Yamamoto K, Mekada E and Sasazuki T: Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells. Cancer Res 60: 6886-6889, 2000. (Pubitemid 32059159)
8. Inokuchi J, Komiya M, Baba I, Naito S, Sasazuki T and Shirasawa S: Deregulated expression of KRAP, a novel gene encoding actin-interacting protein, in human colon cancer cells. J Hum Genet 49: 46-52, 2004. (Pubitemid 38186125)
9. Nordlund P and Reichard P: Ribonucleotide reductases. Annu Rev Biochem 75: 681-706, 2006. (Pubitemid 44118048)
10. Thelander L and Reichard P: Reduction of ribonucleotides. Annu Rev Biochem 48: 133-158, 1979.
11. Schallreuter KU, Elgren TE, Nelson LS Jr., MacFarlan S, Yan-Sze I and Hogenkamp HP: Ribonucleotide diphosphate reductase from human metastatic melanoma. Melanoma Res 2: 393-400, 1992. (Pubitemid 23084487)
12. Liu X, Zhou B, Xue L, Yen F, Chu P, Un F and Yen Y: Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Colorectal Cancer 6: 374-381, 2007. (Pubitemid 46340204)
13. Fan H, Villegas C and Wright JA: Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA 93: 14036-14040, 1996. (Pubitemid 26424241)
14. Duxbury MS, Ito H, Zinner MJ, Ashley SW and Whang EE: RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23: 1539-1548, 2004. (Pubitemid 38406516)
15. Jordheim LP, Guittet O, Lepoivre M, Galmarini CM and Dumontet C: Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther 4: 1268-1276, 2005. (Pubitemid 41149575)
16. Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T and Sznol M: Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res 9: 4092-4100, 2003. (Pubitemid 37204025)
17. Traynor AM, Lee JW, Bayer GK, Tate JM, Thomas SP, Mazurczak M, Graham DL, Kolesar JM and Schiller JH: A phase II trial of triapine (NSC# 663249) and gemcitabine as second-line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. Invest New Drugs 28: 91-97, 2010.
18. Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C and Holen KD: A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs 26: 369-379, 2008.
19. 2-terminal kinase pathway in human colon cancer cells. Cancer Res 59: 2445-2450, 1999. (Pubitemid 29242295)
20. Fujimoto T, Koyanagi M, Baba I, Nakabayashi K, Kato N, Sasazuki T and Shirasawa S: Analysis of KRAP expression and localization, and genes regulated by KRAP in a human colon cancer cell line. J Hum Genet 52: 978-984, 2007. (Pubitemid 350164615)
21. Goldberg L and Kloog Y: A Ras inhibitor tilts the balance between Rac and Rho and blocks phosphatidylinositol 3-kinase-dependent glioblastoma cell migration. Cancer Res 66: 11709-11717, 2006. (Pubitemid 46094183)
22. Gaglio D, Soldati C, Vanoni M, Alberghina L and Chiaradonna F: Glutamine deprivation induces abortive S-phase rescued by deoxyribonucleotides in K-ras transformed fibroblasts. PLoS One 4: e4715, 2009.
23. Furuta E, Okuda H, Kobayashi A and Watabe K: Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta 1805: 141-152,
24. Dang CV and Semenza GL: Oncogenic alterations of metabolism. Trends Biochem Sci 24: 68-72, 1999.
25. 2 gradients in solid tumors in vitro: high-resolution mesurements reveal a lack of correlation. Nat Med 3: 177-182, 1997. (Pubitemid 27064702)
26. Southerland RM: Cell and enviroment interactions in tumor microgenesis: the multicell spheroid model. Science 240: 178-184, 1988.
27. Esumi H, Izuishi K, Kato K, Hashimoto K, Kurashima Y, Kishimoto A, Ogura T and Ozawa T: Hypoxia and nitric oxide treatment confer tolerance to glucose starvation in a 5′-AMP-activated protein kinase-dependent manner. J Biol Chem 277: 32791-32798, 2002. (Pubitemid 34984788)
28. Suzuki A, Kusakai G, Kishimoto A, Lu J, Ogura T and Esumi H: ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation. Oncogene 22: 6177-6182, 2003. (Pubitemid 37281647)
29. Ishii Y, Ogura T, Tatemichi M, Fujisawa H, Otsuka F and Esumi H: Induction of matrix metalloproteinase gene transcription by nitric oxide and mechanisms of MMP-1 gene induction in human melanoma cell lines. Int J Cancer 103: 161-168, 2003. (Pubitemid 35461507)
30. Sato K, Tsuchihara K, Fujii S, Sugiyama M, Goya T, Atomi Y, Ueno T, Ochiai A and Esumi H: Autophagy is activated in colorectal cancer cells and contributes to the tolerance to nutrient deprivation. Cancer Res 67: 9677-9684, 2007. (Pubitemid 47621214)
31. Imamura K, Ogura T, Kishimoto A, Kaminishi M and Esumi H: Cell cycle regulation via p53 phosphorylation by a 5′-AMP-activated protein kinase activator, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 287: 562-567, 2001. (Pubitemid 32917636)